Dear valued Partner,
We are pleased to share an important update regarding Stago's future.
Stago has entered into an exclusive negotiations with ARCHIMED, a healthcare-focused investment firm and La Caisse, also active in the healthcare sector, to support the next phase of our growth.
This step reflects a strategic decision to further strengthen Stago's long-term growth while preserving what has always defined us: scientific excellence, reliability, deep expertise in hemostasis, and a strong commitment to customer partnerships.
This decision reinforces our ability to invest in innovation, accelerate the development of next-generation platforms, and continue delivering high-quality service and support to our customers worldwide.
lmportantly, Stago will remain Stago. Our brand, our values, and our commitment to patient care and customer support remain unchanged.
There will be no disruption to your day-to-day operations, contracts, service agreements, or support structure. Our focus remains exactly where it has always been, on delivering quality, innovation and dependable partnership to you and your laboratory.
We are confident that this step strengthens Stago's foundations and supports our ability to serve you even better over the long term.
As this initiative progresses, we will communicate with you directly as appropriate and share relevant information, reflecting the importance we place on our customers as partners in Stago's journey.
Thank you for your continued trust in Stago.
Jean-Claude Piel